According to reports, after a long battle to take over Mylan, Israeli drugmaker Teva looks to have shifted its focus towards Dublin-based drug giant, Allergan.
If sources are to be believed, the drug maker is in advanced talks to merge with Allergan's generic unit, for a deal of $40-45 billion dollars.
As per sources, the Allergan unit would be spun off and combined with Teva-already the world's biggest seller of generic medicines with a market value of $60 billion.
The deal if materializes would give Teva much bigger footprint in the generic drugs sector and would also offer opportunities for significant cost synergies and tax savings.
The merger would be the latest among big healthcare acquisitions seen in the industry recently. According to analysts, Allergan's generics operations has about $7 billion in sales.
